Launch week offerEnds in00h00m00s

annual Promonthly Pro

Val Gebski

Head of Department

Australia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Australia

About

Val Gebski is the Head of Department at the NHMRC Clinical Trials Centre in Australia. His research focuses on clinical trials and outcomes in oncology, with recent publications addressing topics such as the management of vulvar cancer, oesophago-gastric cancer, and advanced ovarian cancer. Dr. Gebski is also involved in studies related to patient-reported outcomes and neurodevelopmental outcomes in clinical settings.

Articles (13)

Year:

2026

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Collaborators (5)

Qian Shi

Mayo Clinic

UNITED STATES

View details

Jim Codde

Senior Research Fellow

The University of Notre Dame Australia

AUSTRALIA

View details

Sarah (Sally) J Lord

Principal Research Fellow

University of Sydney

AUSTRALIA

View details

Chee Khoon Lee

Professor of Oncology

University of Sydney

AUSTRALIA

View details

Harold Hudson

Emeritus Professor

Macquarie University

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Val Gebski

Research Interests

Make your next move.

Explore related searches

About

Articles (13)

Laparoscopic versus open surgery for rectal cancer: individual patient data meta-analysis of the ALaCaRT and Z6051 randomized trials

Under the radar—frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies

Effect of a correlated competing risk on marginal survival estimation in an accelerated failure time model

Groin Surveillance by Serial Ultrasonography Rather Than Sentinel Node Biopsy or Inguinofemoral Lymphadenectomy for Patients with Vulvar Cancer: A Pilot Study

Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer

A longitudinal cohort study of watch and wait in complete clinical responders after chemo-radiotherapy for localised rectal cancer: study protocol

Adverse events in the placebo arm of maintenance therapy trials in advanced ovarian cancer: A systematic review and meta-analysis

Combination chemotherapy with NAB(R)-paclitaxel and capecitabine for patients with advanced biliary tract cancer (NAP-CAPABIL Pilot Study)

Immune checkpoint inhibitors in kidney transplant recipients: a multicentre, single-arm, phase 1 study

Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial

Neurodevelopmental outcomes of preterm infants after randomisation to initial resuscitation with lower (FiO<sub>2</sub> ≤0.3) or higher (FiO<sub>2</sub> ≥0.6) initial oxygen levels. An individual patient meta-analysis

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

Collaborators (5)

Qian Shi

Jim Codde

Sarah (Sally) J Lord

Chee Khoon Lee

Harold Hudson

Make your next move.